Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 1/2016

01-01-2016 | Research Article

Association between polymorphisms in long non-coding RNA PRNCR1 in 8q24 and risk of gastric cancer

Authors: Lijuan Li, Fu Jia, Peng Bai, Yundan Liang, Ruifen Sun, Fang Yuan, Lin Zhang, Linbo Gao

Published in: Tumor Biology | Issue 1/2016

Login to get access

Abstract

A long ncRNA (lncRNA) prostate cancer non-coding RNA 1 (PRNCR1) in the 8q24 has been reported to be upregulated in prostate cancer with a function of activating androgen receptor (AR). AR plays a key role in the gender disparity, cell migration, and invasion of gastric cancer (GC). We hypothesized that single nucleotide polymorphisms (SNPs) in the lncRNA PRNCR1 may be related to the risk of GC. We conducted a case-control study to investigate the association between SNPs in the lncRNA PRNCR1 and the risk of GC. Polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) assay was used to determine the genotypes of 613 subjects including 219 cases with GC and 394 controls. We found that patients with the rs13252298AG genotype displayed a 1.50-fold increased risk of GC (AG vs. AA, 95 % confidence interval (CI) = 1.05–2.12, p = 0.02). Interestingly, the rs7007694CT and CC and the rs1456315GG genotypes displayed a decreased risk of GC (rs7007694CT vs. TT, odds ratio (OR) = 0.68, 95 % CI = 0.48–0.97, p = 0.03; rs7007694CC vs. TT, OR = 0.36, 95 % CI = 0.13–0.97, p = 0.04; rs1456315GG vs. AA, OR = 0.30, 95 % CI = 0.13–0.70, p = 0.004, respectively). Our results suggest that SNPs in the lncRNA PRNCR1 may be a biomarker for the etiology of GC.
Literature
1.
Gonzalez CA, Sala N, Rokkas T. Gastric cancer: epidemiologic aspects. Helicobacter. 2013;18:34–8.CrossRefPubMed
2.
Jakszyn P, Gonzalez CA. Nitrosamine and related food intake and gastric and oesophageal cancer risk: a systematic review of the epidemiological evidence. World J Gastroenterol WJG. 2006;12:4296–303.CrossRefPubMed
3.
Lee HJ, Yang HK, Ahn YO. Gastric cancer in Korea. Gastr Cancer Off J Int Gastr Cancer Assoc Japan Gastr Cancer Assoc. 2002;5:177–82.
4.
Li L, Feng T, Lian Y, Zhang G, Garen A, Song X. Role of human noncoding RNAs in the control of tumorigenesis. Proc Natl Acad Sci U S A. 2009;106:12956–61.CrossRefPubMedPubMedCentral
5.
Zhang X, Rice K, Wang Y, Chen W, Zhong Y, Nakayama Y, et al. Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions. Endocrinology. 2010;151:939–47.CrossRefPubMed
6.
Pibouin L, Villaudy J, Ferbus D, Muleris M, Prosperi MT, Remvikos Y, et al. Cloning of the mRNA of overexpression in colon carcinoma-1: a sequence overexpressed in a subset of colon carcinomas. Cancer Genet Cytogenet. 2002;133:55–60.CrossRefPubMed
7.
Fu X, Ravindranath L, Tran N, Petrovics G, Srivastava S. Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1. DNA Cell Biol. 2006;25:135–41.CrossRefPubMed
8.
Calin GA, Liu CG, Ferracin M, Hyslop T, Spizzo R, Sevignani C, et al. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell. 2007;12:215–29.CrossRefPubMed
9.
Lin R, Maeda S, Liu C, Karin M, Edgington TS. A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene. 2007;26:851–8.CrossRefPubMed
10.
Burd CE, Jeck WR, Liu Y, Sanoff HK, Wang Z, Sharpless NE. Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk. PLoS Genet. 2010;6:e1001233.CrossRefPubMedPubMedCentral
11.
Chung S, Nakagawa H, Uemura M, Piao L, Ashikawa K, Hosono N, et al. Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci. 2011;102:245–52.CrossRefPubMed
12.
Lochhead P, Ng MT, Hold GL, Rabkin CS, Vaughan TL, Gammon MD, et al. Possible association between a genetic polymorphism at 8q24 and risk of upper gastrointestinal cancer. Eur J Cancer Prev. 2011;20:54–7.CrossRefPubMedPubMedCentral
13.
Guo Y, Fang J, Liu Y, Sheng HH, Zhang XY, Chai HN, et al. Association between polymorphism rs6983267 and gastric cancer risk in Chinese population. World J Gastroenterol. 2011;17:1759–65.CrossRefPubMedPubMedCentral
14.
Wu CW, Chi CW, Chang TJ, Lui WY, P'Eng FK. Sex hormone receptors in gastric cancer. Cancer-Am Cancer Soc. 1990;65:1396–400.
15.
Iushkov PV. Sex hormone receptors in the gastric mucosa in gastric precancer and cancer. Arkh Patol. 1997;59:24–7.PubMed
16.
Polimeno L, Silecchia G, Spaziani E, Scucchi A, Dell'Aquila P, Ierardi E, et al. Estrogens, androgens, and EGF receptor expression in gastric carcinoma induced by N-methyl-N′-nitro-N-nitrosoguanidine. Dig Dis Sci. 1994;39:635–40.CrossRefPubMed
17.
Matsui M, Kojima O, Kawakami S, Uehara Y, Takahashi T. The prognosis of patients with gastric cancer possessing sex hormone receptors. Surg Today. 1992;22:421–5.CrossRefPubMed
18.
Kominea A, Konstantinopoulos PA, Kapranos N, Vandoros G, Gkermpesi M, Andricopoulos P, et al. Androgen receptor (AR) expression is an independent unfavorable prognostic factor in gastric cancer. J Cancer Res Clin Oncol. 2004;130:253–8.CrossRefPubMed
19.
Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst. 2007;99:558–68.CrossRefPubMed
20.
Fang Z, Zhang T, Dizeyi N, Chen S, Wang H, Swanson KD, et al. Androgen receptor enhances p27 degradation in prostate cancer cells through rapid and selective TORC2 activation. J Biol Chem. 2012;287:2090–8.CrossRefPubMed
21.
Li LJ, Sun RF, Liang YD, Pan XM, Li ZH, Bai P, Zeng XF, Zhang DX, Zhang L, and Gao LB. Association between polymorphisms in long non-coding RNA PRNCR1 in 8q24 and risk of colorectal cancer. J Exp Clin Canc Res. 2013;32.
22.
Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, et al. The transcriptional landscape of the mammalian genome. Science. 2005;309:1559–63.CrossRefPubMed
23.
Zaratiegui M, Irvine DV, Martienssen RA. Noncoding RNAs and gene silencing. Cell. 2007;128:763–76.CrossRefPubMed
24.
Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10:155–9.CrossRefPubMed
25.
Costa FF. Non-coding RNAs: Meet thy masters. BioEssays: news and reviews in molecular, cellular and developmental biology. 2010;32:599–608
26.
Orom UA, Derrien T, Beringer M, Gumireddy K, Gardini A, Bussotti G, et al. Long noncoding RNAs with enhancer-like function in human cells. Cell. 2010;143:46–58.CrossRefPubMedPubMedCentral
27.
Yang PK, Kuroda MI. Noncoding RNAs and intranuclear positioning in monoallelic gene expression. Cell. 2007;128:777–86.CrossRefPubMed
28.
Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464:1071–6.CrossRefPubMedPubMedCentral
29.
30.
Zhao Y, Guo Q, Chen J, Hu J, Wang S, Sun Y. Role of long non-coding RNA HULC in cell proliferation, apoptosis and tumor metastasis of gastric cancer: a clinical and in vitro investigation. Oncol Rep. 2014;31:358–64.PubMed
31.
Zhang EB, Kong R, Yin DD, You LH, Sun M, Han L, et al. Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a. Oncotarget. 2014;5:2276–92.CrossRefPubMedPubMedCentral
32.
Zhang EB, Han L, Yin DD, Kong R, De W, Chen J. c-Myc-induced, long, noncoding H19 affects cell proliferation and predicts a poor prognosis in patients with gastric cancer. Med Oncol. 2014;31:914.CrossRefPubMed
33.
Sun M, Jin FY, Xia R, Kong R, Li JH, Xu TP, et al. Decreased expression of long noncoding RNA GAS5 indicates a poor prognosis and promotes cell proliferation in gastric cancer. BMC Cancer. 2014;14:319.CrossRefPubMedPubMedCentral
34.
Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev. 2007;28:778–808.CrossRefPubMed
35.
Tian Y, Wan H, Lin Y, Xie X, Li Z, Tan G. Androgen receptor may be responsible for gender disparity in gastric cancer. Med Hypotheses. 2013;80:672–4.CrossRefPubMed
36.
Zhang BG, Du T, Zang MD, Chang Q, Fan ZY, Li JF, et al. Androgen receptor promotes gastric cancer cell migration and invasion via AKT-phosphorylation dependent upregulation of matrix metalloproteinase 9. Oncotarget. 2014
Metadata
Title
Association between polymorphisms in long non-coding RNA PRNCR1 in 8q24 and risk of gastric cancer
Authors
Lijuan Li
Fu Jia
Peng Bai
Yundan Liang
Ruifen Sun
Fang Yuan
Lin Zhang
Linbo Gao
Publication date
01-01-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3750-2

Other articles of this Issue 1/2016

Tumor Biology 1/2016 Go to the issue

Original Article

The critical role of quercetin in autophagy and apoptosis in HeLa cells

Original Article

Hyperuricemia has an adverse impact on the prognosis of patients with osteosarcoma

Research Article

miR-125/Pokemon auto-circuit contributes to the progression of hepatocellular carcinoma

Original Article

Loss of TIM50 suppresses proliferation and induces apoptosis in breast cancer

Original Article

Mutant-specific BRAF and CD117 immunocytochemistry potentially facilitate risk stratification for papillary thyroid carcinoma in fine-needle aspiration biopsy specimens

Original Article

Downregulated ECRG4 is associated with poor prognosis in renal cell cancer and is regulated by promoter DNA methylation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits